Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

21:25 EST 10th February 2016 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 41

Extremely Relevant

HCW starts Galectin Therapeutics at buy

H.C. Wainwright has initiated coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and 12-month price target of $7. The stock closed at $2.28 on Friday. Galectin is a clinical-stage company focusing on the development of complex carbohydrate compounds that inhibit galectin proteins, which potentially could prevent the progression of and reversal of fibrosis in […]


Relevant

Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" / Interview Airs October 6, 2015, Hosted by Bob "Sully" Sullivan, 3:00pm ET/ 12:00pm PT/ 2:00pm CT

NORCROSS, GA -- (Marketwired) -- 10/06/15 -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced...

Galectin nets $9.2mm through registered direct offering

Galectin Therapeutics Inc. netted $9.2mm through a registered direct offering of 4.76mm common shares at $2.06 (a 17% discount); buyers also received five-year warrants to purchase 3.6mm shares at $2.50. Roth Capital was the placement agent. The company is developing galectin protein-based treatments for fibrotic liver diseases, cancer, and psoriasis.


Galectin initiates Phase IIa pilot trial of GR-MD-02 to treat psoriasis

US-based Galectin Therapeutics has started a ten-patient Phase IIa pilot trial with GR-MD-02, a complex carbohydrate drug, to treat moderate-to-severe plaque psoriasis.

Galectin appoints Dr. Marc Rubin as chairman

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of […]

Galectin Therapeutics to Participate in Three Investment Conferences in September

NORCROSS, Ga., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that executive management will be participating in three investment conferences in September, as follows:  Peter G. Traber, M.D., chief executive officer, president and chief medical officer of Galec...

Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02

NORCROSS, Ga., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the start of a 10-patient pilot study with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. The genesis of this study is the apparent remission of a patient with severe psoriasis who ...

Osteoarthritis: Galectin-1 damages cartilage via inflammation

Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFβ signaling

Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference

NORCROSS, Ga., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Peter G. Traber, M.D., chief executive officer, president, and chief medical officer of Galectin Therapeutics, will make a corporate presentation at the 2015 Ladenburg Thalmann Healthcare Confe...

Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda(R) in Patients With Metastatic Melanoma

NORCROSS, Ga., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that Providence Cancer Center has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to study GR-MD-02 in combination with Keytruda® (pembrolizumab)...

Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering

NORCROSS, Ga., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has entered into securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,761,900 shares of common stock at a price of $2.06 per share ...

Galectin Therapeutics Selected to Present at Cavendish Global Health Impact Forum

NORCROSS, Ga., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th to October 28th at The Cleveland Clinic in Cleveland, Ohio....

Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update

NORCROSS, Ga., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months ended September 30, 2015 and provided a business update. These results are included in the Company's Quarterly Report on Form 10-Q, which has been f...

Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis

NORCROSS, Ga., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the commencement of its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (the NASH-FX trial). This 30-patient study is being conducted...

BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test

WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid...

Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

NORCROSS, Ga., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and six months ended June 30, 2015. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Ex...

Kruppel-like factor 4 (KLF4; EZF); galectin-3 (LGALS3)

Cell culture and mouse studies suggest inhibiting

Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

NORCROSS, Ga., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 13/726,900, titled "Galactose-pronged polysaccharides in a formulation for antifibrotic therapi...

Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

NORCROSS, Ga., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that James Czirr, the Company's Executive Chairman will present at the Robins Equity Research Roundup Conference taking place October 8-10, 2015. Mr. Czirr's presentation, entitled Developing A T...

Exalenz jumps after FDA cirrhosis trial approval

The Israeli firm has received a boost following the announcement of a joint trial with Galectin Therapeutics.

HCW ups La Jolla Pharma price target to $31

H.C. Wainwright has raised its price target for La Jolla Pharmaceutical (NASDAQ:LJPC) to $31 from $20, based on a discounted revenues and earnings valuation methodology. The stock closed at $25.84 on Monday. In May, La Jolla announced that it was sidelining its galectin inhibitor programs in order to reprioritize its pipeline. The restructuring leaves LJPC-501 […]

Finding the “Holy Grail” Treatment for Fatty Livers

When Dr. Peter Traber, the president, CEO and chief medical officer of Galectin Therapeutics, was in medical school, non-alcoholic steatohepatitis (NASH) was an ill-defined liver disease.Read more about Finding the “Holy Grail” Trea

Probably Relevant

Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID® to Monitor Patients with Cirrhosis Associated with NASH

MODI'IN, Israel, Aug. 3, 2015 /PRNewswire/ -- Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics (Nasdaq: GALT) to use the BreathID® test to monitor patients in a Phase II study evaluating GR-MD-02. GR-MD...

A saliva test for heart failure

Queensland University of Technology (QUT) researcher Associate Professor Chamindie Punyadeera has won a $75,000 Heart Foundation Vanguard Grant to assist with the development of a non-invasive screening method for heart failure. The aim of her research project is to produce a test that is quick and easy to administer, by screening saliva instead of blood. Professor Punyadeera explained that heart...


Quick Search
Advertisement
 

News Quicklinks